Ceftriaxone-induced immune hemolytic anemia: a case report
- PMID: 40103810
- PMCID: PMC11913661
- DOI: 10.3389/fimmu.2025.1476563
Ceftriaxone-induced immune hemolytic anemia: a case report
Abstract
Background: Drug-induced immune hemolytic anemia (DIIHA) is a rare but serious disease associated with various antibiotics, which is often misdiagnosed. DIIHA often leads to adverse outcomes, including organ failure and even death. Ceftriaxone is one of the most common drugs that cause DIIHA. This study reports a case of ceftriaxone-induced DIIHA.
Case description: A 5-year-old patient diagnosed with community-acquired pneumonia developed a rash on the 5th day of anti-infective treatment with cefazoxime and azithromycin, followed by a rapid decline in hemoglobin levels and the presence of hemoglobin in the urine (hemoglobinuria). Laboratory analysis showed a positive Coombs' test for the patient. The rash and hematuria subsided after cefazoxime and azithromycin were stopped and symptomatic treatment such as methylprednisolone intravenous infusion, sodium bicarbonate-alkalized urine, enoxaparin sodium anticoagulation, and antiallergic therapy. 5 days later, the child was treated with ceftriaxone for anti-infective therapy because the pneumonia was not healed. During the treatment, the patient suddenly developed itching all over the body, pale face, slightly fast breathing, vomiting, abdominal pain, and low back pain. Immediate cessation of ceftriaxone sodium infusion, continuous nasal catheter oxygen inhalation, normal saline dilatation, and meprednisolone anti-inflammatory and symptomatic treatment of cetirizine were performed. On the evening of the same day, the patient presented with symptoms of wine-colored urine. Laboratory analysis indicated severe anemia and persistent hemolysis, which was considered to autoimmune hemolytic anemia caused by ceftriaxone. After three transfusions and plasma exchange, the patient improved and was discharged from the hospital. One month later, there were no obvious abnormalities in urine analysis, blood routine analysis, reticulocyte analysis, and liver function test.
Conclusion: Understanding the patient's medical history can provide critical information for the diagnosis of DIIHA, and effective management of DIIHA includes immediate discontinuation of suspected drugs, transfusion support, plasma exchange, and symptomatic medication.
Keywords: Coombs’ test; ceftriaxone; decreased hemoglobin; drug-induced immune hemolytic anemia; hemolysis.
Copyright © 2025 Wang, Jiang, Li, Zhang, Qin and Li.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Case report: Decreased hemoglobin and multiple organ failure caused by ceftizoxime-induced immune hemolytic anemia in a Chinese patient with malignant rectal cancer.Front Immunol. 2024 May 2;15:1390082. doi: 10.3389/fimmu.2024.1390082. eCollection 2024. Front Immunol. 2024. PMID: 38756782 Free PMC article.
-
Ceftriaxone-induced hemolytic anemia with severe renal failure: a case report and review of literature.BMC Pharmacol Toxicol. 2018 Oct 25;19(1):67. doi: 10.1186/s40360-018-0257-7. BMC Pharmacol Toxicol. 2018. PMID: 30359322 Free PMC article. Review.
-
Ceftriaxone-Induced Hemolytic Anemia: A Rare Case Report.Perm J. 2020;24:19.088. doi: 10.7812/TPP/19.088. Epub 2019 Dec 18. Perm J. 2020. PMID: 31905339 Free PMC article.
-
Immune hemolytic anemia caused by drugs.Expert Opin Drug Saf. 2012 Jul;11(4):635-42. doi: 10.1517/14740338.2012.678832. Epub 2012 Apr 16. Expert Opin Drug Saf. 2012. PMID: 22502777 Review.
-
Severe drug-induced immune hemolysis due to ceftriaxone.Asian J Transfus Sci. 2020 Jul-Dec;14(2):187-191. doi: 10.4103/ajts.AJTS_67_17. Epub 2020 Dec 19. Asian J Transfus Sci. 2020. PMID: 33767548 Free PMC article.
Cited by
-
Control of type 2 diabetes in patients with cancer and chronic pro-inflammatory cytokines during the COVID-19 pandemic.J Med Life. 2025 May;18(5):428-439. doi: 10.25122/jml-2025-0061. J Med Life. 2025. PMID: 40599143 Free PMC article.
References
-
- Lou C, Liu M, Ma T, Yang L, Long D, Li J, et al. . Case report: Decreased hemoglobin and multiple organ failure caused by ceftizoxime-induced immune hemolytic anemia in a Chinese patient with Malignant rectal cancer. Front Immunol. (2024) 15:1390082. doi: 10.3389/fimmu.2024.1390082 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical